Clinical trial
Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
NCT00067548 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00067548 |
|---|---|
| Title | Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase 2 Study of EKB-569 in Subjects With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung, Lung Neoplasms |
| Intervention type | Drug |
| Interventions | EKB-569 |
| Enrollment | 44 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Aug 25, 2003 |
| Last update posted | Aug 21, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: